一例因伊福斯法米德和阿普雷皮坦特之间药物相互作用引起的脑病变
Tomomi Sano1, Nokitaka Setsu2, Eisuke Kobayashi2
1Department of Pharmacy, National Cancer Center Hospital.
概括
伊福斯法米德 (IFO) 可能导致脑病变,特别是在患有脏问题的老年患者中. 避免服用阿布雷皮坦 (Apr) 和管理胃肠道毒性,可以预防复发.
科学领域:
- 在瘤学瘤学.
- 神经瘤学神经瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 恶性逆上皮质软组织瘤需要积极的治疗.
- 伊福斯法米德 (IFO) 是一种用于治疗各种癌症的化疗剂.
- IFO可能会导致严重的神经副作用,包括脑病变.
研究的目的:
- 在老年患者中报告ifosfamide诱导的脑病变病例.
- 调查阿普雷皮坦在恶化IFO诱导的神经毒性的潜在作用.
- 为突出管理IFO诱导脑病变的策略.
主要方法:
- 一名72岁的男性患者患有逆皮质软组织瘤,接受了ifosfamide.
- 神经症状出现,导致IFO剂量减少和停止治疗.
- 随后的IFO循环用德甲和没有阿普雷皮坦.
主要成果:
- 患者在第一个IFO过程中经历了嗜睡,和妄想.
- 脑病症症状在IFO停止后消失.
- 在较后的循环中没有观察到脑病变的复发,当放弃阿普雷皮坦时.
结论:
- 伊福斯法米德可以诱导严重的脑病变,即使在老年患有功能障碍的患者中降低剂量.
- 同时使用阿普雷皮坦可能会增加ifosfamide诱导脑病变的风险.
- 应考虑使用替代性抗策略,以减轻胃肠道毒性和神经毒性风险.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
221
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
221
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
210
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
210
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
359
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
359
Antiepileptic Drugs: Glutamate Antagonists
435
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
435
Antiepileptic Drugs: GABAergic Pathway Potentiators
474
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
474
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354


